We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
81 hedge funds and large institutions have $428M invested in Crescent Biopharma in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
12% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.03% less ownership
Funds ownership: 1.08% → 1.05% (-0.03%)
5% less funds holding
Funds holding: 85 → 81 (-4)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
36% less capital invested
Capital invested by funds: $668M → $428M (-$240M)
Holders
81
Holders Change
-4
Holders Change %
-4.71%
% of All Funds
1.8%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
28
Reduced
25
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
O
OppenheimerFunds
New York
|
+$3.87M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.75M |
| 3 |
Axa
Paris,
France
|
+$2.21M |
| 4 |
Man Group
London,
United Kingdom
|
+$2.21M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.17M |
Top Sellers
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$6.48M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.12M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$5.76M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.26M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.65M |
